Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported ...

Metsera showed 0% earnings growth in its most recent report, while sales growth came in at 0%. Metsera earns the No. 177 rank among its peers in the Medical-Biomed/Biotech industr ...

Metsera (NASDAQ:MTSR) stock jumps 16% as Wall Street continues to cheer positive Phase 1 data for its weight loss drug ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly ...

Shares of Metsera, Inc. (MTSR) soared 12% on Monday after the company announced positive topline data from an early-stage ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera’s proprietary HALO™ platform technology underpins the development of MET-233i, which aims to offer patients a more convenient dosing schedule with substantial weight loss. The positive trial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...